Dermatology and med-spas

The company shape

Dermatology practices and medical spas operate in overlapping but distinct segments of a combined $22 billion US market. Medical dermatology (skin cancer screening, acne, eczema, psoriasis, dermatitis, cosmetic dermatology) is roughly 12,000 practices with a mix of solo dermatologists, small groups, and increasingly PE-consolidated regional groups. Medical spas (aesthetic services under medical supervision: neurotoxins, dermal filler, laser, energy-based devices, IV therapy, weight-loss injectables) number roughly 12,500 US locations, up from 5,400 in 2018. The two categories overlap when dermatology practices offer cosmetic services alongside medical care.

The category has been reshaped in three ways since 2019. First, GLP-1 medications (semaglutide, tirzepatide) have become a major service line for medical spas, driving 30 to 60 percent revenue lifts at practices that added compounded or brand-name GLP-1 dispensing. Second, private equity consolidation is aggressive in dermatology (Advanced Dermatology, US Dermatology Partners, Forefront Dermatology, Schweiger Dermatology Group, and roughly 25 regional PE platforms). Third, injectable services (Botox, Dysport, Xeomin, Juvederm, Restylane, Sculptra) have commoditized in most metros, with pricing per unit compressing 15 to 25 percent since 2020. Practices that competed on price have squeezed margin. Practices that competed on clinical outcomes and provider identity have held.

Revenue bands cluster into four tiers. The solo dermatologist or NP-owned medspa runs $400K to $1.2M in revenue. The small practice at two to four providers does $1.5M to $5M. The mid-market group at 5 to 12 providers does $5M to $22M. The regional multi-location group does $25M to $120M.

Practice structure runs the physician or NP as the licensed prescribing provider plus aesthetic RNs, injectors, laser technicians, medical assistants, and administrative staff. State regulation varies substantially. Some states allow independent NP-owned medspas, some require physician ownership or oversight, and some restrict certain devices to physician-only use. Scope of practice questions are a real legal risk.

Gross margin structure varies. Medical dermatology (insurance-billed) runs 30 to 45 percent margin at typical reimbursement rates. Cosmetic dermatology (cash-pay) runs 55 to 70 percent margin on services, 25 to 40 percent on injectables (product cost is meaningful), and 60 to 75 percent on laser and energy-based procedures. GLP-1 programs, when structured well, run 55 to 70 percent margin including compounded pharmacy relationships or wholesale purchasing at scale.

GLP-1 program pricing and supply are structural variables that shape 2026 operations. Compounded semaglutide and tirzepatide were widely available through 2023 to 2024, then subject to FDA scrutiny as brand-name manufacturers (Novo Nordisk for Wegovy, Eli Lilly for Zepbound) argued the shortage exceptions permitting compounding were expiring. Practices sourcing compounded medications face ongoing regulatory uncertainty. Practices sourcing brand-name medications through pharmacy partnerships face higher patient costs and lower margins. Both models exist, and the practice's positioning around medication authenticity and cost transparency is a marketing decision as much as an operational one.

The buyer

Dermatology and medspa patients split into four segments. The medical dermatology patient (skin cancer screening, acne, psoriasis, dermatitis; insurance-driven; sometimes converts to cosmetic services later), the injectable patient (Botox, filler; established pattern; recurring 3 to 6 months; $400 to $1,800 per visit), the device patient (laser, IPL, RF microneedling, body contouring; larger case values, $1,200 to $6,500), and the weight-loss patient (GLP-1 program; monthly recurring; $250 to $800 per month depending on medication and dosing).

Medical dermatology patients care about carrier network status, provider credentials (board-certified dermatologist versus mid-level provider), and appointment availability. They find the practice through insurance directory search or Google. Once established, they are moderately loyal and the highest-conversion segment for cosmetic services when the practice's aesthetic offering is present and tastefully positioned.

Injectable patients are the recurring-revenue foundation of most medspas. Average LTV over 3 years is $4,500 to $12,000. They pick a provider (specific person, not just a clinic) and stay if the results are consistent and the experience is good. Provider-specific reviews matter more than clinic-level reviews for this segment. Loyalty programs (Allergan Alle, Galderma Aspire) drive visit frequency and offer additional revenue-tracking benefits.

Device patients research more heavily. They Google specific procedures (Morpheus8, CoolSculpting, IPL for melasma, Sofwave, Ultherapy), read reviews with specific outcome mentions, and often collect two to three consults. Practices with real before/after galleries by procedure, honest downtime and result-timeline content, and clear pricing convert this segment better than practices selling on aspirational marketing alone.

GLP-1 patients are a new segment (2022 to 2026 emergence) with different discovery patterns. They Google "semaglutide near me," "medical weight loss clinic," and specific brand queries. They care about medication authenticity (compounded pharmacy sourcing quality, or brand-name Zepbound/Wegovy availability), monthly cost transparency, provider oversight quality, and outcome tracking. This segment is highly sensitive to safety and legitimacy signaling because of the compounded medication controversies.

Decision drivers across segments, in rough order: provider identity and credentials, reviews (with specifics), before/after evidence for aesthetic services, pricing transparency, and location. Board certification for dermatologists carries a real premium.

Seasonality: cosmetic and device services peak in the two weeks before major events (weddings peak May and September, holiday season October and November) and dip in July and December. Medical dermatology is flat. GLP-1 program starts are heaviest January to March.

Male patient segment growth is a structural shift underway. Male aesthetic patients (Brotox, jawline filler, hair restoration, laser hair removal, body contouring) grew from roughly 10 percent of the aesthetic patient base in 2015 to 20 to 30 percent by 2026 at practices with intentional male-patient positioning. Marketing that acknowledges the male buyer (imagery, treatment framing, provider bios noting male-patient experience) captures this growing share. Practices with feminine-coded marketing miss the segment entirely.

Discovery landscape

Ranked by first-touch attribution for a mid-market practice offering both medical and cosmetic: Google Business Profile takes 28 to 34 percent, Instagram 18 to 25 percent (unusually high for a medical category, driven by the cosmetic side), Google organic 12 to 18 percent, Google Ads 12 to 18 percent, referral (physician and patient) 10 to 15 percent, insurance carrier directory 5 to 10 percent (for the medical segment), and Facebook 3 to 5 percent.

Of the 13 Ranking Surfaces, seven move revenue for dermatology and medspa. LSO leads. SEO with per-service and per-service-city pages captures device and treatment research. E-E-A-T is tier one because YMYL. VxSO because Instagram and before/after search are meaningful discovery channels. AEO for procedure research queries. GEO extends AEO. CWV.

VSO at low volume. Five surfaces do not apply meaningfully. ASO (large DSOs have apps, most independents do not). KGO (rare). GLOBO. Web3. AAO is emerging but not producing volume.

Instagram operates differently for this category than for other medical services. Aesthetic providers who build personal brand on Instagram (specific injector known by name, before/after cadence, treatment education content) drive meaningful revenue directly through the platform. Providers who treat Instagram as a corporate broadcast under-perform. This is one of the few medical categories where personal social media presence of the provider is a real revenue driver.

The RealSelf directory and community forum warrant separate mention. RealSelf is a specialized aesthetic-treatment platform where prospective patients research procedures, compare providers, and read peer reviews from other patients. Board-certified dermatologists and plastic surgeons with active RealSelf profiles receive meaningful inbound from research-heavy prospects, particularly for higher-ticket procedures. Non-physician providers face limited RealSelf presence due to platform rules. Practices with physicians who invest in a proper RealSelf profile (photos, procedure gallery, active Q&A participation) build a compounding channel that operates outside Google.

What breaks most often

Seven failure modes recur.

Compliance shortcuts on before/after photos. HIPAA-compliant patient consent is required and often skipped. Practices posting before/after without documented consent risk both legal exposure and platform bans (Meta and Instagram remove non-compliant content). A formal consent-and-usage process is a compliance requirement, not a nice-to-have.

Provider identity absent or generic. Aesthetic patients hire specific providers. Practices that present provider bios as afterthought (short bio, no photo, no injection philosophy, no signature techniques) lose to practices that build named-provider brands.

GLP-1 messaging either absent or non-compliant. GLP-1 dispensing is a real revenue opportunity but the compliance landscape is fluid (FDA scrutiny of compounded semaglutide, state pharmacy board oversight, advertising restrictions on prescription medications). Practices need to present GLP-1 services with clear medical framing, appropriate disclaimers, and honest content on eligibility, dosing, and side effects.

Pricing hidden. Aesthetic buyers research pricing. Practices with "call for pricing" or vague "starting at" ranges lose to practices with clear per-unit or per-treatment pricing. Injectable pricing per unit (Botox at $12 to $18 per unit depending on metro) is expected transparency in 2026.

Loyalty programs under-utilized. Allergan Alle and Galderma Aspire drive real per-patient value and provide detailed retention data. Practices that do not enroll patients in these programs at consult miss retention and analytics benefits.

Reviews aggregated at clinic level only. Provider-level reviews (specific injector, specific dermatologist) matter more than clinic-level reviews for aesthetic services. Practices need to think about how patients find and evaluate individual providers, not just the location.

Medical dermatology and aesthetic funnels blended. The insurance-driven medical dermatology patient and the cash-pay aesthetic patient want different things from the site. Blending both funnels dilutes both messages. A dedicated aesthetic landing site (or clearly-separated aesthetic section) with cash-pay-appropriate messaging outperforms a single medical-heavy site.

Review generation tied to sales rather than clinical touchpoints. Aesthetic practices that ask for reviews at checkout are asking at the wrong emotional moment. Reviews requested 5 to 7 days after treatment, when the patient sees peak result on injectables or initial improvement on laser, capture higher-quality reviews at higher rates. The delayed request also allows the practice to identify unhappy patients earlier and address concerns before the review gets written.

Ozempic-face and adjacent side-effect content missing. Patients on GLP-1 medications experience visible facial volume loss that drives a new subcategory of aesthetic inquiry (filler for GLP-1-related volume loss, laser and RF treatments to address skin laxity). Practices that offer both GLP-1 programs and volumetric aesthetic services are naturally positioned to serve the full patient journey. Content acknowledging the intersection captures search intent that is growing fast in 2026.

The Ranking Surfaces Playbook applied

Tier one: revenue this quarter

LSO. GBP rebuild with correct primary (Dermatologist for medical-first practices, Medical spa for aesthetic-first, Skin care clinic for balanced). Secondaries for the other services. Precise service area. Weekly Google Posts alternating provider spotlights, treatment education, before/after (compliant), and event or promotion content. Systematic review generation with provider-specific tracking.

SEO. Per-service and per-service-city grid. Dedicated pages for medical dermatology services, each injectable, each device treatment, GLP-1 program, laser categories. Real provider photos, real credentials, real before/after with compliant consent. MedicalBusiness plus LocalBusiness plus FAQPage schema. If the practice has both medical and aesthetic, consider a separate cosmetic site or clearly-separated sections.

E-E-A-T. Tier one for YMYL. Board-certified dermatologist credentials displayed prominently. NP and PA supervising-physician relationships stated. State medical board license numbers. Malpractice insurance disclosure where required by state. Named provider bios with fellowship training, publications if applicable, and professional memberships (AAD, ASDS, ASLMS).

Tier two: compounds

VxSO. Tier two for aesthetic-heavy practices because Instagram and reverse-image search are meaningful. Provider-specific Instagram accounts. Before/after galleries with descriptive alt text. Compliant patient stories with permission.

AEO. Direct-answer guides on 25 to 40 procedure and program research queries. Cost queries, comparison queries (Botox vs Dysport vs Xeomin), procedure detail queries (Morpheus8 downtime, IPL for rosacea), and GLP-1 queries (semaglutide vs tirzepatide, compounded vs brand-name). TL;DR opener, FAQPage schema, real cost tables. Guides reviewed by the physician for YMYL compliance.

GEO. MedicalOrganization schema with sameAs to GBP, LinkedIn, Instagram, state medical board profile, AAD/ASDS profiles. llms.txt in place. Attributable numbered facts.

CWV. Mobile-first. LCP under 2s.

Tier three: lower ROI, low cost

VSO. Speakable markup on FAQ blocks.

Tier four: not a fit

ASO, KGO (unless notable), GLOBO, Web3, AAO. Skip AAO for now.

How Playbook priority shifts by practice size

Solo NP medspa or dermatologist under $1.2M: LSO plus a tight site, provider bio, review generation, basic Instagram. Skip most of the compounding stack. Small practice $1.5M to $5M: full LSO, per-service pages, injectable pricing published, basic content engine. Attribution stack essential. Mid $5M to $22M: full Playbook subset. AEO on procedure queries. GLP-1 program with compliant framing as a separate landing section. Provider-specific brand building. Regional $25M+: multi-location measurement, KGO consideration for notable providers, custom patient portal app potentially triggering ASO.

First 30 / 60 / 90 days

Days 1 to 30

Attribution deployment. Baseline cost per new patient by channel, by service line (medical, injectable, device, GLP-1). GBP rebuild with correct primary. Provider bios with credentials, fellowship, and injection or clinical philosophy published. HIPAA-compliant patient consent process for before/after photos and testimonials established. Review generation flow live with provider-specific tracking. Instagram audit: provider-specific accounts audited or established for the main injectors and physicians.

Days 31 to 60

Site restructure. If the practice mixes medical and aesthetic heavily, plan a dedicated aesthetic sub-site or clearly-separated sections. Per-service and per-service-city grid built. Dedicated pages for each injectable, each device, GLP-1 program with compliant framing, and each medical dermatology service. Pricing bands published (per-unit for injectables, per-treatment for devices). Before/after galleries with compliant consent. CWV in green. First six AEO guides live, reviewed by the physician.

Days 61 to 90

Loyalty program enrollment operationalized (Allergan Alle, Galderma Aspire, patient enrolled at consult). Retention sequences activated (injectable patients get automated recall reminders at 90 to 150 day intervals depending on product). GLP-1 patients get monthly follow-up communication for program adherence. Twelve AEO guides live cumulative. GEO entity clarity in place. Rank tracking on procedure-and-city and provider-name terms. First map-pack gains between day 60 and 90. Realistic year-one outcomes: 25 to 45 percent lift in new consult bookings, injectable retention up 8 to 15 points, and provider-specific reviews growing at 20 to 40 per month per busy injector.

Measurement stack across the 90-day window

GA4 with events for consult_request, new_patient_form, financing_click, service_book, glp1_intake_start. CallRail with unique numbers per channel. Practice management (Nextech, Symplast, Aesthetics Pro typical) with contact source, service line, and provider on every appointment. Loyalty programs (Alle, Aspire) integrated for retention analytics. Weekly dashboard covering new consult volume, consult-to-treatment conversion, retention by provider, GLP-1 program adherence, and review count. Cost caps: paid media at 5 to 8 percent of trailing revenue (higher because aesthetic CPCs are elevated). SEO and content at 1 to 2 percent. Photography for before/after (with compliant consent) at 1 to 2 percent.